Clarification on the Impact of Cervarix Vaccination on Human Papillomavirus Infection and Cervical Cancer in the United Kingdom

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials

(2015) Aimée R Kreimer et al.   LANCET ONCOLOGY

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

(2014) Paulo S Naud et al.   Human Vaccines & Immunotherapeutics

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

(2012) Talía Malagón et al.   LANCET INFECTIOUS DISEASES

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Impact of vaccinating boys and men against HPV in the United States

(2010) Elamin H. Elbasha et al.   VACCINE

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET